Barclays
FDMT icon

Barclays’s 4D Molecular Therapeutics FDMT Stock Holding History

Barclays’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.57M Buy
179,867
+156,042
+655% +$2.03M ﹤0.01% 2439
2026
Q2 		$317K Sell
23,825
-1,612
-6% -$15.7K ﹤0.01% 3468
2026
Q1 		$237K Sell
25,437
-145,202
-85% -$1.26M ﹤0.01% 3588
2025
Q4 		$1.28M Buy
170,639
+76,811
+82% +$779K ﹤0.01% 3264
2025
Q3 		$815K Sell
93,828
-17,951
-16% -$107K ﹤0.01% 3493
2025
Q2 		$415K Buy
111,779
+14,737
+15% +$51.8K ﹤0.01% 3866
2025
Q1 		$313K Sell
97,042
-8,203
-8% -$38.6K ﹤0.01% 3808
2024
Q4 		$586K Sell
105,245
-9,603
-8% -$75.4K ﹤0.01% 3728
2024
Q3 		$1.24M Buy
114,848
+67,202
+141% +$1.12M ﹤0.01% 3213
2024
Q2 		$1M Sell
47,646
-173
-0.4% -$4.34K ﹤0.01% 2601
2024
Q1 		$1.52M Sell
47,819
-60,890
-56% -$1.55M ﹤0.01% 2789
2023
Q4 		$2.2M Buy
108,709
+34,774
+47% +$458K ﹤0.01% 2839
2023
Q3 		$941K Sell
73,935
-68,529
-48% -$1.15M ﹤0.01% 2375
2023
Q2 		$2.57M Buy
142,464
+85,235
+149% +$1.57M ﹤0.01% 1718
2023
Q1 		$984K Buy
57,229
+22,556
+65% +$439K ﹤0.01% 2743
2022
Q4 		$770K Buy
34,673
+23,297
+205% +$360K ﹤0.01% 3008
2022
Q3 		$91K Buy
11,376
+1,760
+18% +$15.9K ﹤0.01% 3571
2022
Q2 		$68K Sell
9,616
-2,340
-20% -$22.7K ﹤0.01% 3924
2022
Q1 		$181K Buy
+11,956
New +$188K ﹤0.01% 3480

Other funds holding FDMT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Perigon Wealth Management
Perigon Wealth Management San Francisco, California $6.5B AUM 20.72% 1-Year Est. Return
Hussman Strategic Advisors
Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Barclays's FDMT Position: Q3 2026 in Review

Barclays increased its 4D Molecular Therapeutics (FDMT) stake by 655% in Q3 2026, buying an estimated $2.03M and bringing the position to 179,867 shares worth $2.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2439.

Barclays first reported a position in FDMT in Q1 2022 and has held it in 19 quarters since. The position peaked at $2.57M in Q2 2023. 53 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Barclays held 179,867 shares of 4D Molecular Therapeutics worth $2.57M as of Q3 2026.
  • Barclays bought 156,042 4D Molecular Therapeutics shares in Q3 2026, an estimated $2.03M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2439 holding.
  • Barclays first reported a position in 4D Molecular Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's 4D Molecular Therapeutics position peaked at $2.57M in Q2 2023.
  • 53 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.